drugset / Trial / NCT01257542
Acute Cough Study In Children
Phase 4
Terminated
140 enrolled
Pfizer
AccuDial Pharmaceutical, Inc. · collabBoehringer Ingelheim · collabMcNeil Consumer Healthcare Division of McNEIL-PPC, Inc. · collabNovartis · collabPerrigo Company · collabProcter and Gamble · collabReckitt Benckiser Inc. · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
15 mg dextromethorphan hydrobromide will be better than placebo with respect to reducing the number of coughs over 6 hours and reducing the subjective severity of cough over 6 hours.
Timeline
- Start
- 2010-12
- Primary completion
- 2011-03
- Completion
- 2011-03
Outcome
Missed primary endpoint
Stopped: “See termination reason in detailed description.”
registry Placebo vs Dextromethorphan Hydrobromide; p = 0.252 NCT01257542 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dextromethorphan | Unknown | 15 mg | — |